Abstract
Purpose
Management of patients with synchronous hepatic metastases as the sole metastatic site at diagnosis of gastric cancer is debated. We studied a cohort of patients admitted to surgical units, investigating prognostic factors of clinical relevance and the results of various therapeutic strategies.
Methods
Retrospective multicentre chart review. We evaluated how survival from surgery was influenced by patient-related, gastric cancer-related, metastasis-related and treatment-related candidate prognostic factors.
Results
Forty-four patients received palliative surgery without resection, 98 palliative gastrectomy (in 16 cases associated with R+ hepatectomy), whereas 53 patients received both curative gastrectomy and hepatic resection(s) (R0). Adjuvant chemotherapy was administered to 44 patients. Therapeutic approach was selected on the basis of extension of disease, patient’s general conditions and surgeon’s attitude. Surgical mortality was 4.6 % and morbidity was 17.4 %. Survival was independently influenced by the factor T of the gastric primary (p = 0.036) and by the degree of hepatic involvement (p = 0.010). T > 2 and H3 liver involvement were associated with worse prognosis with cumulative effect (p = 0.002). Therapeutic approach to the metastases (p = 0.009) and adjuvant chemotherapy (p < 0.001) displayed independent impact upon survival, with benefit for those receiving aggressive multimodal treatment. The 1-, 3-, and 5-year survival rates were 50.4, 14.0, and 9.3 %, respectively, for patients submitted to curative surgery, 16, 8.5, and 4.3 % after palliative gastrectomy, and 6.8, 2.3, and 0 % after palliative surgery without resection.
Conclusions
Our data suggest some clinical criteria that may facilitate selection of candidates to curative surgery, which offers the best survival chances, especially when associated with adjuvant chemotherapy.
Similar content being viewed by others
References
Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524–35.
Lehner F, Ramackers W, Bektas H, et al. Liver resection for non-colorectal, non-neuroendocrine liver metastases—is hepatic resection justified as part of the oncosurgical treatment? Zentralbl Chir. 2009;134:430–6.
Ochiai T, Sasako M, Mizuno S, et al. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg. 1994;81:1175–8.
Ueda K, Iwahashi M, Nakamori M, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009;394:647–53.
Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002;235:86–91.
Hwang S-E, Yang D-H, Kim C-Y. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg. 2009;33:1468–72.
Tiberio GAM, Coniglio A, Marchet A, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35:486–91.
Makino H, Kunisaki C, Izumisawa Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticanc Res. 2010;30:2367–76.
Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001;181:279–83.
Miyazaki M, Itoh H, Nakagawa K, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol. 1997;92:490–93.
Shirabe K, Shimada M, Matsumata T, et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology. 2003;50:1560–3.
Sakamoto Y, Sano T, Shimada K, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007;95:534–9.
Thelen A, Jonas S, Benckert C, et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34:1328–34.
Tsujimoto H, Ichikura T, Ono S, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010;4:406–13.
Garancini M, Uggeri F, Degrate L, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile? HPB. 2012;14:209–15.
Schildberg CW, Croner R, Merkel S, et al. Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis. World J Surg. 2012;36:872–8.
Miki Y, Fujitani K, Hirao M, et al. Significance of surgical treatment of liver metastases from gastric cancer. Anticancer Res. 2012;32:665–70.
Takemura N, Saiura A, Koga R, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012;397:951–7.
Liu J, Li JH, Zhai RJ, et al. Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases. Chin Med J (Engl). 2012;125:165–71.
Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma. Review and considerations for future directions. Ann Surg. 2005;241:27–39.
Liu J, Chen L. Current status and progress in gastric cancer with liver metastasis. Chin Med J (Engl). 2011;124:445–56.
Tiberio GAM, Portolani N, Giulini SM. Hepatic metastases from gastric cancer. In: Mahmoud L, editor. Gastric carcinoma—molecular aspects and current advances. InTech. 2011. doi:10.5772/16638.
Kerkar SP, Kemp CD, Avital I. Liver resections in metastatic gastric cancer. HPB. 2010;12:589–96.
Chiche L, Ducreux M, Lebreton G, et al. Métastases hépatiques des cancers de l’estomac. In: Adam R, Chiche L, editors. Chirurgie des métastases hépatiques de cancers non colorectaux non endocrine. Monographies de l’association Française de Chirurgie. Paris: Arnette; 2005. p. 45–9.
Edge SB, Byrd DR, Compton CC, eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English ed. Gastric Cancer. 2011;14:101–12.
Marrelli D, De Stefano A, de Manzoni G, et al. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.
Imamura H, Matsuyama Y, Shimada R, et al. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol. 2001;96:3178–84.
Roh HR, Suh KS, Lee HJ, et al. Outcome of hepatic resection for metastatic gastric cancer. Am Surg. 2005;71:95–9.
Yang XW, Li Z, Liu K, et al. Correlation between the survival rate of the patients with synchronous hepatic metastases from gastric carcinoma after surgical resection and patient’s index. Chin Med J. 2012;125:747–51.
Wang YN, Shen KT, Ling JQ, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012;12:20.
Shirabe K, Wakiyama S, Gion T, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB. 2006;8:89–92.
Cheon SH, Rha SY, Jeung H-C, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19:1146–153.
Kim HR, Cheon SH, Lee KH, et al. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2010;26:305–15.
Misleh JG, Santoro P, Strasser JF, et al. Multidisciplinary management of gastric cancer. Surg Oncol Clin N Am. 2013;22:247–64.
Hartgrink HH, Putter H, Klein Kranenbarg E, et al. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438–43.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
Acknowledgment
The authors are grateful to Mr. Richard Humphies (BA Hons English Literature) for his precious help in revising the English language of the manuscript.
Disclosure
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
On behalf of the Italian Research Group for Gastric Cancer.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
Effect of chemotherapy. A Survival according to chemotherapy. B Cumulative survival according to the number of negative prognostic factors related to gastric primary (T > 2) and hepatic involvement (H3). Supplementary material 3 (TIFF 60 kb)
Rights and permissions
About this article
Cite this article
Tiberio, G.A.M., Baiocchi, G.L., Morgagni, P. et al. Gastric Cancer and Synchronous Hepatic Metastases: Is It Possible to Recognize Candidates to R0 Resection?. Ann Surg Oncol 22, 589–596 (2015). https://doi.org/10.1245/s10434-014-4018-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-014-4018-6